Background:​ Novo Nordisk developed the world’s first oral GLP-1 receptor agonist (RA) — a groundbreaking innovation in the treatment of type 2 diabetes. After 15 years of research and development, oral semaglutide marks a major scientific milestone: making GLP-1 therapy available in pill form for the first time.

​

Insight: The journey from lab to life was long, complex, and highly technical — making it challenging to communicate clearly. To truly convey the significance of this breakthrough, we needed a visual storytelling approach that simplified the science without losing its impact.

 

Creative Execution: We developed a clean, modern visual language brought to life through animation and print. A short animated video and accompanying booklet broke down the scientific process into an engaging, easy-to-follow narrative — guiding the viewer through the 15-year journey in a clear, compelling way.